Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hageboutros

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Molecular Pharmacology|March 1, 1997
Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatmentK S Yao, A Hageboutros, P Ford, et al.
Pharmacotherapy|March 1, 1996
Acute encephalopathy attributed to 5-FUC J Langer, A Hageboutros, D D Kloth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 1999
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracilM R Johnson, A Hageboutros, K Wang, et al.
Investigational New Drugs|January 1, 1997
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancerA Hageboutros, G R Hudes, F Greene, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancerA Hageboutros, A Rogatko, E M Newman, et al.
Bone Marrow Transplantation|February 1, 1997
The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferonJ Gryn, E Johnson, N Goldman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleosideA Hageboutros, G R Hudes, J Brennan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Molecular Pharmacology|March 1, 1997
Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatmentK S Yao, A Hageboutros, P Ford, et al.
Pharmacotherapy|March 1, 1996
Acute encephalopathy attributed to 5-FUC J Langer, A Hageboutros, D D Kloth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 1999
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracilM R Johnson, A Hageboutros, K Wang, et al.
Investigational New Drugs|January 1, 1997
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancerA Hageboutros, G R Hudes, F Greene, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancerA Hageboutros, A Rogatko, E M Newman, et al.
Bone Marrow Transplantation|February 1, 1997
The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferonJ Gryn, E Johnson, N Goldman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleosideA Hageboutros, G R Hudes, J Brennan, et al.
Pageof 1